Danaher Announces New Localization Strategy with Northern China Headquarters and Synthetic Biology Platform in Beijing

Jan 17, 2024 17:54 CST Updated 17:55

Danaher

Product Design and Manufacturer

Instrument Family

Medical Device Media Reporting Pioneer

Share Professional Medical Device Knowledge

Source: Danaher

Danaher Northern Headquarters and Synthetic Biology Manufacturing Platform Established in Changping, Beijing

January 16, 2024Zhi Xianwei, District Mayor of Changping District, Beijing, and Director of the Future Science City Management Committee, met with Mr. Ian Williamson, Global Executive Vice President of Danaher Corporation and Global President of its Medical Diagnostics Platform.(Joakim Weidemanis) held a discussion and exchange at Zhongguancun Life Science Park, and signed a cooperation agreement for the establishment of Danaher's Northern Headquarters and a common technology platform for synthetic biomanufacturing in Changping.

Wei Youan said,Danaher continues to be optimistic about the Chinese market, adhering to its "In China, For China" development strategy. It is committed to strengthening the local industrial chain and ecosystem by deepening cooperation with Changping District, accelerating the upgrading of the large health industry, and contributing to Healthy China 2030.

Li Lei, President of Danaher China Life Sciences Platform, stated,As a global leader in science and technology, Danaher focuses on fields such as life sciences, medical diagnostics, and biotechnology, providing customers with solutions in five key areas: medical diagnostics, antibody development, process development and preclinical research, process scale-up and clinical research, and commercial production. These efforts support fundamental scientific research, the development of innovative drugs and new therapies, accelerate the translation of research achievements into clinical applications, and enhance the diagnostic capabilities and laboratory management levels of medical institutions.

Danaher and Changping District share the same development philosophy. They will establish a science and innovation center, which will also serve as the Northern Headquarters of Danaher Group, integrating product display, customer experience, and course training to support industrial development. Together, they will build a synthetic biomanufacturing technology platform. This platform will include a strain construction and screening platform centered on high-throughput automation equipment, as well as a mass spectrometry detection technology application platform. Once completed, it will become an important public technology service platform for the synthetic biomanufacturing industry layout in Changping District.

Wei Chunyan, Vice President of External Affairs at Danaher China, stated,Continuously explore innovative models for the transformation of achievements, bring clinical PI to Changping with the establishment of the Northern Headquarters, and realize innovative transformation in Changping. Meanwhile, on the basis of cooperation in synthetic biology, promote better industrial innovation.

Danaher Collaborates with Nobel Laureate Jennifer Doudna to Launch CRISPR Gene Editing Therapy Development Project

On January 9, 2024, Danaher Corporation and the Innovative Genomics Institute (IGI) announced the establishment of a joint research and development center to jointly develop gene editing therapies for treating rare diseases and other conditions, creating a new model for the future development of various gene-based medicines.The R&D center, named Danaher-IGI Beacon for CRISPR Cures, aims to permanently treat hundreds of diseases through integrated research, development, and regulation, utilizing CRISPR-based gene editing technology.

Nobel laureate, CRISPR pioneer, and IGI founder Jennifer Doudna, together with Fyodor Urnov, IGI’s Director of Technology and Translation and the new Beacon Project Director, will oversee the development of research initiatives at IGI headquarters. Both are professors at the University of California, Berkeley. IGI Executive Director Brad Ringeisen will also play a key role in the new research center. As a global innovator in life sciences and medical diagnostics, Danaher will provide extensive technical support and solutions for the production of CRISPR therapies while developing new technologies and methods to streamline and standardize preclinical and clinical development.

Nobel Prize Winner, CRISPR Pioneer, and IGI Founder Jennifer Doudna

This collaboration represents the largest Beacon project by Danaher to date and will enable IGI to launch significant new research initiatives. The Danaher Beacon Project aims to fund cutting-edge scientific research in academic institutions, developing innovative technologies and applications that improve human health. The project focuses on areas including genomic medicine, precision diagnostics, next-generation biologics manufacturing, human systems, and data science.

Rainer M. Blair, President and Chief Executive Officer of Danaher Corporation, said"CRISPR holds tremendous promise for disease treatment, but there is currently no standardized academic or regulatory framework to guide how we apply it to patients. To address such a significant challenge, we need to bring together academia, industry, and government to collaborate. We are excited to join forces with the most outstanding researchers in the field of gene editing from IGI, combining the talent, technology, and expertise from Danaher's multiple operating companies in research and production, to create revolutionary solutions for critically important yet underserved patients."

Doudna stated"The new joint R&D center combines the respective strengths of IGI and Danaher, offering a unique and powerful way to fulfill the promise of CRISPR therapy. We know how to deliver CRISPR molecules to target tissues. We understand the patient population. Our team includes world-class experts in researching these diseases. Together, we need to map out a blueprint that outlines all the science and technology required for using CRISPR therapies. Once this is achieved, I firmly believe CRISPR will become the standard for clinical treatment of many diseases." As a first step, the Danaher-IGI Beacon project will develop gene-editing therapies for two types of inborn errors of immunity (IEIs) — Hemophagocytic Lymphohistiocytosis (HLH) and Artemis-deficient Severe Combined Immunodeficiency (Artemis-SCID). Both parties believe that several characteristics of IEIs make them suitable for the Danaher/IGI joint approach, including extensive patient records and transplant-based delivery methods, which help overcome some key challenges in delivering CRISPR molecules to target tissues.

In general, IEIs encompass approximately 500 distinct diseases, affecting hundreds of thousands of people worldwide. However, they are not currently the primary focus of any major gene-editing trials, largely because designing and testing therapies for each very small population of IEI patients is challenging, slow, and costly. Given CRISPR's unique ability to be easily reprogrammed to address any genetic mutation, the goal of the Danaher-IGI Beacon for CRISPR Cures is to develop a scalable platform-based approach to rapidly create new treatments, even for diseases beyond IEIs. The aim of the Beacon project is to ensure that the platform-based methods developed by the joint research center can be expanded to cover more IEIs and other rare diseases, as well as more common conditions treatable by editing a single specific gene.

END

2,300 Units: Mindray Secures Major U.S. Order

Medtronic, Johnson & Johnson's Partner, Giant's New Acquisition

Over 20 Million Units: Global Ventilator Giant Issues Level One Recall

World's First, MR-Guided Proton Therapy System

Medtronic: Plans to Close Five Production Bases

Focusing on Localization, Another Medical Device Giant Lands in China

Top 100 Medical Device Companies Restructure, Cut 5% of Workforce

JPM24: Top Ten Medical Device Events

Giant with 90 Billion Yuan in Revenue Plans to Spin Off Healthcare Unit for IPO

9,428 Units: Johnson & Johnson Subsidiary Issues Class I Recall

BusinessBusiness cooperation email: qxzj@landianyiliao.com